6125 results
Cited 1 times since 2023 (0.5 per year)
source: EuropePMC
Circulation. Arrhythmia and electrophysiology,
Volume 16, Issue 2, 25 4 2023, Pages e011676
Prognostic Implications of Right Ventricular Size and Function in Patients Undergoing Cardiac Resynchronization Therapy.
Galloo X, Stassen J, Hirasawa K, Mertens BJA, Cosyns B, van der Bijl P, Delgado V, Ajmone Marsan N, Bax JJ
Abstract
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,
Volume 31, Issue 2, 24 4 2023, Pages 85-86
Albert Bruschke (1935-2022), a pioneer of coronary arteriography.
van Hemel N, Jukema JW
Abstract
Cited 2 times since 2023 (1 per year)
source: EuropePMC
Clinical cardiology,
Volume 46, Issue 3, 24 4 2023, Pages 320-327
Risk factors based vessel-specific prediction for stages of coronary artery disease using Bayesian quantile regression machine learning method: Results from the PARADIGM registry.
Park HB, Lee J, Hong Y, Byungchang S, Kim W, Lee BK, Lin FY, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Chun EJ, Cademartiri F, Maffei E, Marques H, Gonçalves PA, Leipsic JA, Shin S, Choi JH, Virmani R, Samady H, Chinnaiyan K, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Kook W, Chang HJ
Background and hypothesis: The recently introduced Bayesian quantile regression (BQR) machine-learning method enables comprehensive analyzing the relationship among complex clinical variables. We analyzed the relationship between multiple cardiovascular (CV) risk factors and different stages of coronary artery disease (CAD) using the BQR model in a vessel-specific manner. Methods: From the data of 1,463 patients obtained from the PARADIGM (NCT02803411) registry, we analyzed the lumen diameter st...
Abstract
Cited 1 times since 2023 (0.5 per year)
source: EuropePMC
JACC. Clinical electrophysiology,
Volume 9, Issue 7 Pt 1, 18 3 2023, Pages 965-975
Volume-Weighted Unipolar Voltage Predicts Heart Failure Mortality in Patients With Dilated Cardiomyopathy and Ventricular Arrhythmias.
Kimura Y, Beukers HKC, Rademaker R, Chen HS, Ebert M, Jensen T, Piers SR, Wijnmaalen AP, de Riva M, Dekkers OM, Stevenson WG, Zeppenfeld K
Background: Patients with dilated cardiomyopathy (DCM) who are undergoing catheter ablation of ventricular arrhythmias (VAs) are at risk of rapidly progressive heart failure (HF). Endocardial voltages decrease with loss of viable myocardium. Global left ventricular (LV) voltage as a surrogate for the amount of remaining viable myocardium may predict prognosis. Objectives: This study evaluated whether the newly proposed parameter volume-weighted (vw) unipolar voltage (UV) can predict HF-related a...
Abstract
Cited 29 times since 2023 (13.8 per year)
source: EuropePMC
JACC. Clinical electrophysiology,
Volume 9, Issue 4, 18 3 2023, Pages 511-522
Very High-Power Ablation for Contiguous Pulmonary Vein Isolation: Results From the Randomized POWER PLUS Trial.
O'Neill L, El Haddad M, Berte B, Kobza R, Hilfiker G, Scherr D, Manninger M, Wijnmaalen AP, Trines SA, Wielandts JY, Gillis K, Lycke M, De Becker B, Tavernier R, Le Polain De Waroux JB, Knecht S, Duytschaever M
Background: Very high-power, short-duration (90-W/4-second) ablation for pulmonary vein isolation (PVI) may reduce procedural times. However, shorter applications with higher power may impact lesion quality. Objectives: In this multicenter, randomized controlled trial, the authors compared procedural efficiency, efficacy, and safety of PVI using 90-W/4-second ablation to 35/50-W ablation. Methods: Patients with paroxysmal or persistent atrial fibrillation undergoing first-time PVI were randomize...
Abstract
Cited 1 times since 2023 (0.5 per year)
source: EuropePMC
The Pediatric infectious disease journal,
Volume 42, Issue 4, 18 3 2023, Pages e129
Nowadays a New MIS-C Mimicker: Group A Streptococcal Infections.
Elvan-Tuz A, Elvan-Tuz A, Ekemen-Keles Y, Karadag-Oncel E, Yilmaz D, Ozcifci G, Durak F
Abstract
Cited 2 times since 2023 (0.9 per year)
source: EuropePMC
JACC. Clinical electrophysiology,
Volume 9, Issue 6, 18 3 2023, Pages 740-748
Head-to-Head Comparison of T1 Mapping and Electroanatomical Voltage Mapping in Patients With Ventricular Arrhythmias.
Sramko M, Abdel-Kafi S, Wijnmaalen AP, Tao Q, van der Geest RJ, Lamb HJ, Zeppenfeld K
Background: Electroanatomical voltage mapping (EAVM) has been compared with late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR), which cannot delineate diffuse fibrosis. T1-mapping CMR overcomes the limitations of LGE-CMR, but it has not been directly compared against EAVM. Objectives: This study aims to assess the relationship between left ventricular (LV) endocardial voltage obtained by EAVM and extracellular volume (ECV) obtained by T1 mapping. Methods: The study investiga...
Abstract
Cited 2 times since 2023 (0.9 per year)
source: EuropePMC
Annals of vascular surgery,
Volume 93, 13 2 2023, Pages 283-290
Evaluation of the Angiosome Concept Using Near-Infrared Fluorescence Imaging with Indocyanine Green.
Tange FP, Ferrari BR, van den Hoven P, van Schaik J, Schepers A, van Rijswijk CSP, van der Meer RW, Putter H, Vahrmeijer AL, Hamming JF, van der Vorst JR
Background: The angiosome concept is defined as the anatomical territory of a source artery within all tissue layers. When applying this theory in vascular surgery, direct revascularization (DR) is preferred to achieve increased blood flow toward the targeted angiosome of the foot in patients with lower extremity arterial disease (LEAD). This study evaluates the applicability of the angiosome concept using quantified near-infrared (NIR) fluorescence imaging with indocyanine green (ICG). Methods:...
Abstract
Cited 1 times since 2023 (0.5 per year)
source: EuropePMC
Frontiers in cardiovascular medicine,
Volume 9, 12 2 2023, Pages 1036522
Risk for acquired coronary artery disease in genetic vs. congenital thoracic aortopathy.
Dolmaci OB, Ayyildiz T, Poelmann RE, Driessen AHG, Koolbergen DR, Klautz RJM, Lindeman JHN, Grewal N
Objective: Patients with Marfan syndrome (MFS) and patients with a bicuspid aortic valve (BAV) have a significantly increased risk to develop thoracic aortopathy. Both conditions share many pathophysiological mechanisms leading to aortic complications. Bicuspidy is known to have a low risk for acquired coronary artery sclerosis. The aim of this study is to determine the risk of coronary sclerosis in MFS patients. Methods: Marfan syndrome patients with an aortic root dilatation, which were surgic...
Abstract
Cited 2 times since 2023 (0.9 per year)
source: EuropePMC
European journal of medical research,
Volume 28, Issue 1, 11 2 2023, Pages 22
Comparison of telemonitoring combined with intensive patient support with standard care in patients with chronic cardiovascular disease - a randomized clinical trial.
Öner A, Dittrich H, Arslan F, Hintz S, Ortak J, Brandewiede B, Mann M, Krockenberger K, Thiéry A, Ziegler A, Schmidt C, CardioCare MV Study Group
Importance: Healthcare concepts for chronic diseases based on tele-monitoring have become increasingly important during COVID-19 pandemic. Objective: To study the effectiveness of a novel integrated care concept (NICC) that combines tele-monitoring with the support of a call centre in addition to guideline therapy for patients with atrial fibrillation, heart failure, or treatment-resistant hypertension. Design: A prospective, parallel-group, open-label, randomized, controlled trial. Setting: Bet...
Abstract
Cited 5 times since 2023 (2.3 per year)
source: EuropePMC
Frontiers in cardiovascular medicine,
Volume 9, 9 2 2023, Pages 1032755
Are acute type A aortic dissections atherosclerotic?
Grewal N, Dolmaci O, Jansen E, Klautz R, Driessen A, Lindeman J, Poelmann RE
Background: Type A aortic dissections (TAAD) are devastating aortic complications. Patients with Marfan syndrome, a bicuspid aortic valve or a thoracic aortic aneurysm have an increased risk to develop a TAAD. These predisposing conditions are characterized by a histologically thin intimal layer and hardly any atherosclerosis. Little is known about the susceptibility for atherosclerosis in patients with a type A aortic dissection. Objective: We aim to systematically describe atherosclerotic lesi...
Abstract
Cited 8 times since 2023 (3.7 per year)
source: EuropePMC
Vascular pharmacology,
Volume 148, 7 1 2023, Pages 107141
The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.
Laufs U, Catapano AL, De Caterina R, Schiele F, Sionis A, Zaman A, Jukema JW
Aims: To evaluate the effect of the ESC/EAS 2019 dyslipidaemia guidelines on patient management of lipid-lowering therapy in patients with acute coronary syndrome (ACS), through a survey designed to compare post-ACS patient management in 2022 with that in 2018. Methods: Online questionnaires focused on lipid profile and medications were used to gather data from 2650 ACS patients in 6 European countries, treated between March-June 2022 (ACS EuroPath IV survey). These data were compared with data...
Abstract
Cited 2 times since 2023 (0.9 per year)
source: EuropePMC
Cellular signalling,
Volume 104, 5 1 2023, Pages 110587
Early adipogenesis is repressed through the newly identified FHL2-NFAT5 signaling complex.
Clemente-Olivo MP, Hernández-Quiles M, Sparrius R, van der Stoel MM, Janssen V, Habibe JJ, van den Burg J, Jongejan A, Alcaraz-Sobrevals P, van Es R, Vos H, Kalkhoven E, de Vries CJM
The LIM-domain-only protein FHL2 is a modulator of signal transduction and has been shown to direct the differentiation of mesenchymal stem cells towards osteoblast and myocyte phenotypes. We hypothesized that FHL2 may simultaneously interfere with the induction of the adipocyte lineage. Therefore, we investigated the role of FHL2 in adipocyte differentiation. For these studies pre-adipocytes isolated from mouse adipose tissue and the 3T3-L1 (pre)adipocyte cell line were applied. We performed FH...
Abstract
Cited 1 times since 2023 (0.5 per year)
source: EuropePMC
Circulation. Arrhythmia and electrophysiology,
Volume 16, Issue 1, 3 1 2023, Pages e010826
Pleomorphic Ventricular Tachycardia in Dilated Cardiomyopathy Predicts Ventricular Tachycardia Recurrence After Ablation Independent From Cardiac Function: Comparison With Patients With Ischemic Heart Disease.
Kimura Y, de Riva M, Ebert M, Glashan C, Wijnmaalen AP, Piers SR, Dekkers OM, Trines SA, Zeppenfeld K
Background: In dilated cardiomyopathy (DCM), outcome after catheter ablation of ventricular tachycardia (VT) is modest, compared with ischemic heart disease (IHD). Pleomorphic VT (PL-VT) has been associated with fibrotic remodeling and end-stage heart failure in IHD. The prognostic role of PL-VT in DCM is unknown. Methods: Consecutive IHD (2009-2016) or DCM (2008-2018) patients undergoing ablation for monomorphic VT were included. PL-VT was defined as ≥1 spontaneous change of the 12-lead VT-morp...
Abstract
Journal of the American College of Cardiology,
Volume 81, Issue 3, 1 1 2023, Pages e25
Reply: Outcomes in Bicuspid Aortic Valve Disease.
Hecht S, Bax JJ, Pibarot P
Abstract
Cited 22 times since 2023 (10.2 per year)
source: EuropePMC
European heart journal,
Volume 44, Issue 1, 1 1 2023, Pages 28-40
Valvular heart disease: shifting the focus to the myocardium.
Ajmone Marsan N, Delgado V, Shah DJ, Pellikka P, Bax JJ, Treibel T, Cavalcante JL
Adverse cardiac remodelling is the main determinant of patient prognosis in degenerative valvular heart disease (VHD). However, to give an indication for valvular intervention, current guidelines include parameters of cardiac chamber dilatation or function which are subject to variability, do not directly reflect myocardial structural changes, and, more importantly, seem to be not sensitive enough in depicting early signs of myocardial dysfunction before irreversible myocardial damage has occurr...
Abstract
Cited 32 times since 2023 (14.8 per year)
source: EuropePMC
European heart journal,
Volume 44, Issue 3, 1 1 2023, Pages 176-177
The '10 commandments' for the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
Tfelt-Hansen J, Winkel BG, de Riva M, Zeppenfeld K
Abstract
Cited 2 times since 2023 (0.9 per year)
source: EuropePMC
Age and ageing,
Volume 52, Issue 1, 1 1 2023, Pages afac312
Weight loss, visit-to-visit body weight variability and cognitive function in older individuals.
Zonneveld MH, Noordam R, Sabayan B, Stott DJ, Mooijaart SP, Blauw GJ, Jukema JW, Sattar N, Trompet S
Objective: to investigate the association between variability and loss of body weight with subsequent cognitive performance and activities of daily living in older individuals. Design: cross-sectional cohort study. Setting: PROspective Study of Pravastatin in the Elderly at Risk, multicentre trial with participants from Scotland, Ireland and the Netherlands. Subjects: 4,309 participants without severe cognitive dysfunction (mean age 75.1 years, standard deviation (SD) = 3.3), at higher risk for...
Abstract
Cited 2 times since 2023 (0.9 per year)
source: EuropePMC
European heart journal,
Volume 44, Issue 2, 1 1 2023, Pages 159-161
Guideline-based use of cardiac imaging for chronic coronary syndromes.
van der Bijl P, Stassen J, Bax JJ
Abstract
Cited 4 times since 2023 (1.9 per year)
source: EuropePMC
Clinical and translational allergy,
Volume 13, Issue 1, 1 1 2023, Pages e12221
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease.
Achten R, Thijs J, van der Wal M, van Luijk C, van Luin M, El Amrani M, Knol E, Delemarre E, Jager CDH, de Graaf M, Bakker D, de Boer J, van Wijk F, de Bruin-Weller M
Background: The patho-mechanism of ocular surface disease (OSD) in dupilumab-treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patients. Methods: This prospective study included dupilumab-treated moderate-to-severe AD patients who were seen by a dermatologist and an ophthalmologist before the start of dupilumab (baseline), and afte...
Abstract
